Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRC

August 21, 2015
Eric Van Cutsem, MD, PhD

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).

Eric Van Cutsem, MD, PhD, University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). He and his colleagues conducted the nonrandomized, phase IIIb CONSIGN study, in order to examine the effects of regorafenib in these previously treated patients.

After seeing the CORRECT study, which showed that regorafenib improves survival, the goal of the CONSIGN study was to include a larger number of patients, said Van Cutsem. The primary endpoint was to look at the safety of regorafenib and learn more about how to improve tolerance of the drug.